SLC5A2 and type 2 diabetes mellitus: For MBG, SGLT-2 inhibitors or GLP-1 agonists contributed more to the reduction in type 1 diabetes than in type 2 diabetes (SMD = −0.56, 95% CI = −0.65 to −0.47 vs. SMD = −0.28, 95% CI = −0.55 to −0.01; Figure 4b).